JP2011529503A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529503A5
JP2011529503A5 JP2011521235A JP2011521235A JP2011529503A5 JP 2011529503 A5 JP2011529503 A5 JP 2011529503A5 JP 2011521235 A JP2011521235 A JP 2011521235A JP 2011521235 A JP2011521235 A JP 2011521235A JP 2011529503 A5 JP2011529503 A5 JP 2011529503A5
Authority
JP
Japan
Prior art keywords
acid
compound
alcohol
cis
double bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011521235A
Other languages
English (en)
Japanese (ja)
Other versions
JP5653917B2 (ja
JP2011529503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/051927 external-priority patent/WO2010014585A1/en
Publication of JP2011529503A publication Critical patent/JP2011529503A/ja
Publication of JP2011529503A5 publication Critical patent/JP2011529503A5/ja
Application granted granted Critical
Publication of JP5653917B2 publication Critical patent/JP5653917B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011521235A 2008-07-28 2009-07-28 神経変性疾患の治療のためのｐｋｃ活性化化合物 Expired - Fee Related JP5653917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8417208P 2008-07-28 2008-07-28
US61/084,172 2008-07-28
PCT/US2009/051927 WO2010014585A1 (en) 2008-07-28 2009-07-28 Pkc-activating compounds for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014182597A Division JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物

Publications (3)

Publication Number Publication Date
JP2011529503A JP2011529503A (ja) 2011-12-08
JP2011529503A5 true JP2011529503A5 (enExample) 2012-09-13
JP5653917B2 JP5653917B2 (ja) 2015-01-14

Family

ID=41136734

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011521235A Expired - Fee Related JP5653917B2 (ja) 2008-07-28 2009-07-28 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2014182597A Pending JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2016051212A Expired - Fee Related JP6449186B2 (ja) 2008-07-28 2016-03-15 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2018111869A Pending JP2018168170A (ja) 2008-07-28 2018-06-12 神経変性疾患の治療のためのｐｋｃ活性化化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014182597A Pending JP2015042643A (ja) 2008-07-28 2014-09-08 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2016051212A Expired - Fee Related JP6449186B2 (ja) 2008-07-28 2016-03-15 神経変性疾患の治療のためのｐｋｃ活性化化合物
JP2018111869A Pending JP2018168170A (ja) 2008-07-28 2018-06-12 神経変性疾患の治療のためのｐｋｃ活性化化合物

Country Status (6)

Country Link
US (7) US8163800B2 (enExample)
EP (3) EP3586839A1 (enExample)
JP (4) JP5653917B2 (enExample)
CA (2) CA2731171C (enExample)
ES (1) ES2683021T3 (enExample)
WO (1) WO2010014585A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090030055A1 (en) * 2002-07-02 2009-01-29 Thomas Nelson PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds
EP3586839A1 (en) 2008-07-28 2020-01-01 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
WO2011102907A1 (en) * 2010-02-22 2011-08-25 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
US9107890B2 (en) 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
KR102110200B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 산화성 망막 질환
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
US20140235496A1 (en) 2011-10-05 2014-08-21 Blanchette Rockefeller Neurosciences Drive Stimulus-elicited genomic profile markers of a neurodegenerative condition
JP6422778B2 (ja) * 2011-11-13 2018-11-14 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃアクチベーターおよびその組合せ
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
WO2014126191A1 (ja) * 2013-02-15 2014-08-21 株式会社西崎創薬研究所 シクロプロパン環を有する不飽和脂肪酸誘導体を含むリン脂質化合物
JP2016516201A (ja) * 2013-03-15 2016-06-02 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 神経保護性ｐｋｃ活性化因子を特定する方法
ES2732153T3 (es) 2013-10-18 2019-11-20 Blanchette Rockefeller Neurosciences Inst Esteres halogenados de ácidos grasos insaturados ciclopropanados para su utilización en el tratamiento de las enfermedades neurodegenerativas
KR20170031653A (ko) 2014-04-18 2017-03-21 뉴로트롭 바이오싸이언스 인크. 지질 축적 장애의 치료를 위한 방법 및 조성물
US9413754B2 (en) 2014-12-23 2016-08-09 Airwatch Llc Authenticator device facilitating file security
JP2018521113A (ja) 2015-05-11 2018-08-02 アルコン、ダニエル・エル． ＡｐｏＥ４対立遺伝子の存在を決定した後のＰＫＣ活性化因子を使用した神経変性状態の治療
WO2017053659A1 (en) 2015-09-23 2017-03-30 Khan Tapan K Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
WO2017062924A1 (en) 2015-10-08 2017-04-13 Alkon Daniel L Dosing regimens of pkc activators
CN108698987B (zh) 2015-11-23 2021-07-13 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
JP6912072B2 (ja) * 2016-12-14 2021-07-28 国立大学法人山口大学 前頭側頭型認知症の予防又は治療用医薬
WO2018187647A1 (en) 2017-04-06 2018-10-11 Neurotrope Bioscience, Inc. Methods and compositions for treatment of neurological diseases, disorders, or conditions
EP3964210A1 (en) * 2018-05-18 2022-03-09 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
US20220023255A1 (en) * 2018-12-07 2022-01-27 The Johns Hopkins University Methods, compositions and kits for treating multiple sclerosis and other disorders
KR20260018193A (ko) 2020-02-21 2026-02-06 레트로토프 인코포레이티드 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
US20220133687A1 (en) * 2020-11-02 2022-05-05 Synaptogenix, Inc. Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US20240180869A1 (en) * 2021-02-08 2024-06-06 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
US20240165075A1 (en) * 2021-02-08 2024-05-23 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
WO2023225073A1 (en) * 2022-05-18 2023-11-23 Virginia Commonwealth University Methods for treatment of cognitive impairment in cirrhosis patients
WO2025056602A1 (en) 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US20030108956A1 (en) 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6017887A (en) 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6001580A (en) 1995-03-28 1999-12-14 Takeda Chemical Industries, Inc. Method for assaying ERK2 map kinase
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1997032020A2 (en) 1996-02-29 1997-09-04 Mount Sinai Hospital Corporation Shc proteins
JPH1090263A (ja) 1996-07-25 1998-04-10 Mclean Hospital Corp:The アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用
WO2000020867A1 (en) 1998-10-01 2000-04-13 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
AU5150300A (en) 1999-05-19 2000-12-05 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
WO2001027624A2 (en) 1999-10-08 2001-04-19 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
JP2003527604A (ja) 2000-03-10 2003-09-16 ワシントン・ユニバーシティ 個々の細胞の標識方法
JP2003528071A (ja) 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
EP1268434A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
CA2404273A1 (en) 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
JP2004502665A (ja) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
EP1315971A2 (en) 2000-07-31 2003-06-04 The Regents of The University of California Model for alzheimer's disease and other neurodegenerative diseases
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
AUPR215700A0 (en) 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
EP1390404A2 (en) 2000-12-21 2004-02-25 Novartis AG Interleukin-1 related gene and protein
CA2437497A1 (en) 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules
ATE394115T1 (de) 2001-02-27 2008-05-15 Brni Neurosciences Inst Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung
JP4024554B2 (ja) 2001-02-27 2007-12-19 松下電器産業株式会社 燃料電池発電システム
US6874208B2 (en) 2001-03-14 2005-04-05 Autoliv Asp, Inc. Anchoring attachment apparatus
WO2003002122A1 (en) 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20040014678A1 (en) 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
WO2004083241A2 (en) 2003-03-19 2004-09-30 Takeda Pharmaceutical Company Limited Btc-interacting proteins and use thereof
WO2006050475A2 (en) 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
CA2582270A1 (en) 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease
US20090182021A1 (en) 2005-08-03 2009-07-16 Nanternet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
EP1934618B1 (en) 2005-10-11 2009-05-13 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
WO2007043998A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio
JP2009541863A (ja) 2006-06-21 2009-11-26 レキシコル メディカル テクノロジー エルエルシー 痴呆および痴呆型障害を分析および評価するためのシステムおよび方法
JP2008143819A (ja) * 2006-12-08 2008-06-26 Tomoyuki Nishizaki 酸化ストレス誘導細胞死の抑制剤
KR20140049054A (ko) 2007-02-09 2014-04-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
US20100209914A1 (en) 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
EP2767541A1 (en) * 2008-03-03 2014-08-20 Rxbio, Inc. LPA receptor agonists and antagonists
EP3586839A1 (en) 2008-07-28 2020-01-01 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2018168170A5 (enExample)
Kumar et al. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
JP2014512351A5 (enExample)
NZ626699A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
JP2020500193A5 (enExample)
Auvin Fatty acid oxidation and epilepsy
JP2010196060A5 (enExample)
JP2010519311A5 (enExample)
US10576053B2 (en) Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
JP2016538254A5 (enExample)
JP2015143248A5 (enExample)
Kawashima et al. Effects of eicosapentaenoic acid on synaptic plasticity, fatty acid profile and phosphoinositide 3-kinase signaling in rat hippocampus and differentiated PC12 cells
CN104684389A (zh) 含有天然专门促消退介质及其前体的具有抗炎活性的油
JP2012516852A5 (enExample)
JP2016501248A5 (enExample)
JP2017526623A5 (enExample)
RU2019110681A (ru) Фармацевтическая композиция
Basselin et al. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation
JP7242769B2 (ja) 遊離多価不飽和脂肪酸含有組成物及びその製造方法
JP2016501249A5 (enExample)
JP2020182497A5 (enExample)
CA3001018A1 (en) Oil compositions and methods of making
Clarke et al. Chain reactions: early-life stress alters the metabolic profile of plasma polyunsaturated fatty acids in adulthood
JP2012513380A5 (enExample)
JP2016523826A5 (enExample)